British drugmaker GSK said on Tuesday its experimental therapy, linerixibat, met its main goal in a late-stage trial to treat ...
A judge in the U.K. last month sided with Pfizer over GSK in a respiratory syncytial virus vaccine patent lawsuit, ...
The GSK share price has tumbled recently on a number of factors, but I think its fundamentals look strong, leaving the stock ...
GSK's phase 3 GLISTEN trial demonstrated linerixibat's potential to treat relentless itch in PBC patients, meeting its ...
A phase 3 trial of GSK’s linerixibat in a liver disease has hit its primary endpoint, keeping the drugmaker on track to ...
The GSK share price has been in a strong freefall after peaking at 1,785p in September. Most recently, the GSK stock ...
Cairo – GlaxoSmithKline (GSK Egypt) registered an annual growth in consolidated net profit after tax to EGP 105.82 million during the first nine months (9M) of 2024, versus EGP 46.73 million.
GSK (GSK) announced headline results of GLISTEN, the ongoing global phase III clinical trial evaluating linerixibat, an investigational targeted inhibitor of the ileal bile acid transporter, IBAT, in ...
GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...
GSK announces positive results from GLISTEN phase III trial of linerixibat in adults with cholestatic pruritus (relentless itch) associated with PBC: London, UK Wednesday, Novembe ...
Vesalius Therapeutics' deal with GSK centers around discovering and developing new treatments for Parkinson’s disease, and ...
Though GSK has put considerable effort into developing pharmacological treatments for gynecological cancers—including Zejula, ...